November 18, 2020
Source: PLoS One. 2020 Nov 18;15(11):e0242092. doi: 10.1371/journal.pone.0242092. eCollection 2020.
Authors: Anna Grohová , Klára Dáňová , Irena Adkins , Zdeněk Šumník , Lenka Petruželková , Barbora Obermannová , Stanislava Koloušková , Radek Špíšek , Lenka Palová-Jelínková
Myeloid-derived suppressor cells (MDSC) represent a heterogeneous group of immature myeloid cells with immunoregulatory function in cancer and autoimmune diseases. In humans, two subsets of MDSC were determined based on the characteristic surface markers, monocytic MDSC (M-MDSC) and granulocytic MDSC (G-MDSC). Expansion of MDSC has been reported in some murine models and patients with autoimmune diseases and their immune-suppressive properties were characterized. However, the exact role of MDSC in the pathogenesis of autoimmune diseases is more complex and/or controversial. In type 1 diabetes mellitus (T1D), the increased frequency of MDSC was found in the blood of T1D patients but their suppressor capacity was diminished. In our study, we assessed the role of M-MDSC in the pathogenesis of T1D and showed for the first time the increased frequency of M-MDSC not only in the blood of T1D patients but also in their at-risk relatives compared to healthy donors. T1D patients with inadequate long term metabolic control showed an elevation of M-MDSC compared to patients with better disease control. Furthermore, we described the positive correlation between the percentage of M-MDSC and Th17 cells and IFN-γ producing T cells in T1D patients and their at-risk relatives. Finally, we found that the ability of M-MDSC to suppress autologous T cells is efficient only at the high MDSC: T cells ratio and dependent on cell-cell-contact and TGF-β production. Our data show that the engagement of MDSC in the pathogenesis of T1D is evident, yet not entirely explored and more experiments are required to clarify whether MDSC are beneficial or harmful in T1D.
Conflict of interest statement
Lenka Palová Jelinková, Klára Dáňová, Irena Adkins, and Radek Spisek are employees of Sotio a.s., Prague, Czech Republic. Lenka Palová-Jelínková, Klára Dáňová, and Radek Špíšek are named inventors in the patent, “Tolerogenic Dendritic Cells, Methods of Producing the Same, and Uses Thereof” (U.S. Provisional Application No. 62/066,994), which describes methods for the preparation of stable semi-mature tolerogenic DC. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The other authors have no financial conflicts of interest.